List of Excipients in Branded Drug IVERMECTIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Padagis US LLC	IVERMECTIN	ivermectin	0574-2107	CARBOMER COPOLYMER TYPE B
Padagis US LLC	IVERMECTIN	ivermectin	0574-2107	CETYL ALCOHOL
Padagis US LLC	IVERMECTIN	ivermectin	0574-2107	CITRIC ACID MONOHYDRATE
Padagis US LLC	IVERMECTIN	ivermectin	0574-2107	DIMETHICONE
Padagis US LLC	IVERMECTIN	ivermectin	0574-2107	EDETATE DISODIUM
Padagis US LLC	IVERMECTIN	ivermectin	0574-2107	GLYCERIN
Padagis US LLC	IVERMECTIN	ivermectin	0574-2107	ISOPROPYL PALMITATE

Generic Drugs Containing IVERMECTIN

Company	Ingredient	NDC	Excipient
Walgreen Company	ivermectin	0363-4230	ANHYDROUS CITRIC ACID
Walgreen Company	ivermectin	0363-4230	ANHYDROUS TRISODIUM CITRATE
Walgreen Company	ivermectin	0363-4230	BUTYLATED HYDROXYANISOLE
Walgreen Company	ivermectin	0363-4230	CASTOR OIL
Walgreen Company	ivermectin	0363-4230	CETYL ALCOHOL
Walgreen Company	ivermectin	0363-4230	CYCLOMETHICONE
Walgreen Company	ivermectin	0363-4230	GLYCERIN

What are the Most Frequently-Used Excipients in IVERMECTIN?

# Of NDCs	Excipient
14	ANHYDROUS CITRIC ACID
10	ANHYDROUS TRISODIUM CITRATE
2	BENZYL ALCOHOL
12	BUTYLATED HYDROXYANISOLE
2	CARBOMER COPOLYMER TYPE B
2	CARBOMER HOMOPOLYMER TYPE C
10	CASTOR OIL

Ivermectin Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: August 30, 2026

Ivermectin is a mature, low-cost antiparasitic with substantial formulation opportunity despite limited composition-of-matter protection. Its low aqueous solubility, high lipophilicity, dose-dependent tolerability, and multiple approved delivery routes create opportunities in oral bioavailability, topical delivery, veterinary long-acting products, pediatric dosage forms, and differentiated global products. The strongest commercial positions are likely to come from proprietary formulations, manufacturing processes, delivery devices, and regulated product claims rather than from the ivermectin molecule itself.

What is the commercial status of ivermectin?

Ivermectin is approved for human and veterinary use in oral, topical, and veterinary dosage forms. Human indications include strongyloidiasis, onchocerciasis, head lice, and inflammatory lesions of rosacea, depending on the product and jurisdiction.[1-4]

Product or category	Dosage form	Representative strength	Primary market	Commercial position
Stromectol	Tablet	3 mg	Strongyloidiasis and onchocerciasis	Originator product with generic competition
Generic ivermectin	Tablet	3 mg	Antiparasitic indications	Broad ANDA competition
Soolantra	Cream	1%	Rosacea	Branded topical product with generic and follow-on risk
Sklice	Lotion	0.5%	Head lice	Branded topical product with generic and OTC-adjacent competition
Veterinary ivermectin	Injectable, paste, pour-on, chewable, tablet	Product-specific	Livestock, equine, companion animals	Large, fragmented global market

Ivermectin is not a biologic and therefore does not face biosimilar competition. The relevant FDA pathway for conventional products is the abbreviated new drug application, or ANDA, rather than a 351(k) biosimilar application.

The main commercial constraints are low active pharmaceutical ingredient cost, extensive generic availability, mature manufacturing know-how, and limited ability to command a premium without a meaningful clinical or usability advantage.

What excipient problems must an ivermectin formulation solve?

Ivermectin is practically insoluble in water and highly lipophilic. These properties can limit dissolution, absorption consistency, content uniformity, and patient acceptability. The formulation strategy depends on the route.

Oral formulations

The main oral challenge is improving dissolution without creating an unstable or manufacturing-sensitive product. Conventional ivermectin tablets commonly use relatively simple excipient systems. The Stromectol label identifies microcrystalline cellulose, pregelatinized starch, magnesium stearate, and butylated hydroxyanisole as inactive ingredients.[1]

A conventional immediate-release tablet can be commercially attractive because it has low manufacturing cost and a straightforward regulatory pathway. Its disadvantages are limited differentiation and weak intellectual-property protection.

Potential oral excipient strategies include:

Strategy	Candidate excipient or platform	Commercial objective	Main development issue
Wetting and dissolution enhancement	Surfactants, poloxamers, sodium lauryl sulfate	Improve dissolution rate	Irritation, taste, regulatory limits
Lipid-based delivery	Medium-chain triglycerides, lipid excipients, self-emulsifying systems	Increase apparent solubility and absorption	Food effect, capsule compatibility, stability
Amorphous solid dispersion	Polymer carriers such as PVP, copovidone, HPMC-based systems	Maintain a supersaturated solution after dosing	Recrystallization and scale-up
Nanocrystals	Stabilizers such as poloxamers or cellulosic polymers	Increase surface area and dissolution	High-pressure processing and physical stability
Cyclodextrin complexation	Hydroxypropyl-beta-cyclodextrin and related materials	Improve apparent aqueous solubility	Excipient load, cost, dose volume
Granulation and particle engineering	Micronized or engineered ivermectin particles	Improve content uniformity and dissolution	Dust control and reproducibility

The strongest generic-development opportunities are likely to involve a bioequivalent immediate-release product with improved manufacturability, lower excipient burden, or a more robust dissolution profile. A premium product would need a clinically relevant benefit, such as reduced food dependence, improved pediatric dosing, or a lower dose burden.

Topical formulations

Topical ivermectin products must balance drug release, skin deposition, spreadability, irritation, preservative performance, and patient sensory attributes.

Soolantra 1% cream uses a conventional semisolid vehicle containing ingredients including carbomer, cetyl alcohol, citric acid, dimethicone, disodium edetate, glycerin, isopropyl palmitate, methylparaben, phenoxyethanol, propylene glycol, sorbitan monostearate, stearyl alcohol, and purified water.[2]

A topical development program can target several distinct outcomes:

• Higher ivermectin deposition in the stratum corneum and pilosebaceous unit.
• Lower systemic exposure.
• Reduced greasiness or tack.
• Faster drying and improved cosmetic acceptability.
• Lower preservative burden.
• Better compatibility with sensitive or atopic skin.
• More consistent dose delivery from a pump or metered applicator.
• Improved stability under high-temperature distribution conditions.

The most defensible excipient claims will generally concern composition, phase structure, particle size, viscosity, release rate, or delivery performance. Broad claims that merely recite ivermectin in a cream are vulnerable because topical ivermectin formulations are well established.

Lotion and rinse-off products

Sklice 0.5% lotion uses a low-viscosity topical vehicle designed for scalp and hair application. Its labeled inactive ingredients include alcohols, citric acid, isopropyl myristate, medium-chain triglycerides, methylparaben, phenoxyethanol, polysorbate 20, propylene glycol, sorbitan monolaurate, stearyl alcohol, and purified water.[3]

Commercial differentiation may come from:

• A non-greasy lotion with improved combability.
• A lower-odor system.
• A silicone-based vehicle.
• A single-dose package.
• A pediatric-friendly applicator.
• A formulation that reduces residue after rinsing.
• Packaging that improves scalp coverage and reduces product waste.

Because head-lice treatment is highly consumer-sensitive, usability can be as important as pharmacokinetic performance. An excipient system that improves application time, washability, or perceived cleanliness may support a stronger brand position than a small change in dissolution.

What formulations are most commercially attractive?

The most attractive formulation concepts fall into four groups.

1. Long-acting veterinary formulations

Veterinary ivermectin has the broadest opportunity for differentiated delivery. Candidate platforms include injectable depots, intraruminal systems, sustained-release implants, pour-on formulations, and long-acting oral products.

The value proposition is operational rather than purely pharmacological:

• Fewer dosing events.
• Better herd compliance.
• Lower labor cost.
• Improved parasite-control scheduling.
• More consistent exposure across animals.
• Reduced handling stress.

Potential excipients include biodegradable polymers, oleaginous vehicles, suspending agents, viscosity modifiers, and depot-forming systems. The regulatory burden is significant because tissue residues, withdrawal periods, environmental exposure, target-animal safety, and resistance management must be demonstrated.

Veterinary formulations also face an important technical risk: prolonged subtherapeutic exposure can contribute to anthelmintic resistance. A long-acting product must demonstrate adequate exposure duration without creating an extended low-concentration tail.

2. Pediatric oral products

A child-friendly ivermectin formulation could target patients who cannot swallow tablets. Options include oral dispersible tablets, granules, mini-tablets, suspensions, and unit-dose sachets.

Key excipient requirements include:

• Palatability and taste masking.
• Low viscosity at the intended dose.
• Minimal sedimentation or rapid redispersion.
• Safe dosing across a broad weight range.
• Stability without excessive preservative use.
• Simple administration in low-resource settings.

Taste-masking approaches may use polymer coatings, ion-exchange resins, lipid barriers, sweeteners, flavors, or multiparticulate systems. The commercial opportunity is stronger in pediatric and mass-drug-administration settings than in routine adult tablet markets.

3. High-performance topical products

A next-generation rosacea product could compete through better tolerability, faster onset, lower application frequency, or improved cosmetic properties. Possible platforms include emulsions, microemulsions, lamellar creams, polymeric gels, nanodispersions, and follicular-targeting systems.

The development risk is that improved in vitro release does not automatically produce better clinical outcomes. A formulation that increases skin penetration may also increase irritation or systemic exposure. The best patent strategy would connect composition parameters to measurable performance, such as skin retention, release kinetics, tolerability, or reduced application frequency.

4. Solubility-enhanced oral products

An oral product using a lipid-based system, amorphous dispersion, or nanocrystal technology could target more consistent exposure. The commercial value would depend on demonstrating a benefit over standard tablets, such as reduced variability, reduced dependence on a high-fat meal, or lower dose.

A formulation that only improves dissolution in vitro may have limited market value because generic ivermectin tablets are inexpensive and widely available. Clinical pharmacokinetic data and a clear labeling advantage are more valuable than laboratory dissolution data alone.

How strong is the patent estate for ivermectin formulations?

The ivermectin molecule is old, and its core composition-of-matter protection has expired. The current patent opportunity is concentrated in secondary protection.

IP category	Typical claim scope	Relative strength
Composition of matter	Ivermectin or avermectin derivative	Very weak for new market entry
Conventional tablet	Ivermectin with standard fillers and lubricants	Weak
Novel oral delivery system	Lipid, nanocrystal, dispersion, or complexation platform	Moderate if supported by data
Topical composition	Defined vehicle, phase system, or excipient ratio	Moderate
Method of treatment	Specific indication, dosing schedule, or patient population	Variable
Manufacturing process	Particle engineering, granulation, coating, or sterile processing	Moderate if difficult to design around
Device and packaging	Metered pump, applicator, unit-dose system	Narrow but commercially useful
Veterinary depot	Long-acting release profile and formulation architecture	Potentially strong

Patent strength depends on claim breadth, enablement, prior art, freedom to operate, and the ability to show a clinically meaningful advantage. Formulation patents with only broad ingredient lists are vulnerable to written-description and obviousness challenges. Narrow claims tied to physicochemical parameters, release profiles, stability results, or pharmacokinetic data are more defensible.

Geographic coverage should be prioritized according to the product. For human topical products, the United States, European Union, Japan, China, South Korea, Brazil, and Australia are key markets. For veterinary products, the United States, European Union, Australia, Brazil, India, and major livestock-producing jurisdictions warrant separate analysis because residue rules and registration requirements differ.

When does ivermectin lose exclusivity?

Ivermectin has already lost primary exclusivity in the United States. Generic oral ivermectin products are widely marketed, and the commercial barrier for a new tablet is generally regulatory equivalence, manufacturing scale, distribution, and price.

For branded topical products, exclusivity is more product-specific. The relevant analysis requires review of:

• FDA Orange Book patent listings.
• Regulatory exclusivity attached to the NDA.
• Approved indications.
• Listed formulation or method-of-use patents.
• Paragraph IV certifications.
• District court litigation.
• Any settlement or license agreements.
• State substitution and pharmacy-channel effects.

Soolantra and Sklice have a different competitive profile from Stromectol because topical products can retain commercial value through vehicle design, brand recognition, prescriber habits, and patient preference. Still, topical generic entry can materially reduce price and market share once an ANDA is approved and substitutable.

What is the Orange Book and Paragraph IV risk for ivermectin?

The Orange Book is central to U.S. market-entry analysis for listed human drug products. A generic applicant may file a Paragraph IV certification asserting that a listed patent is invalid, unenforceable, or not infringed. The filing can trigger patent litigation and, in some circumstances, a 30-month stay of FDA approval under the Hatch-Waxman framework.[5]

For ivermectin, risk differs by product:

Product	Primary generic risk	Paragraph IV relevance
Stromectol tablets	High, because oral generics are established	Mainly relevant to any remaining listed patents or new branded products
Soolantra cream	Moderate to high, depending on approved generic status and listed patents	Relevant to formulation and method-of-use patents
Sklice lotion	Moderate, with risk concentrated in vehicle and treatment claims	Relevant where listed patents remain enforceable
New oral delivery system	Product-specific	Potentially significant if listed patents cover the formulation
New veterinary product	Jurisdiction-specific	Controlled through national veterinary approval and patent systems

A Paragraph IV strategy is most effective when a challenger can design around narrow formulation claims or invalidate claims based on known topical bases, pharmaceutical excipients, or predictable solubility-enhancement techniques. A sponsor can improve defensive value by claiming a defined formulation architecture and supporting it with comparative clinical or pharmacokinetic evidence.

What litigation and settlement issues affect ivermectin?

The principal legal risk is generic substitution rather than biosimilar litigation. Ivermectin’s age reduces the value of molecule-level litigation, while secondary patents can be challenged through invalidity, noninfringement, and obviousness arguments.

Potential dispute areas include:

• Whether a generic cream falls within a listed formulation patent.
• Whether a method-of-use patent is infringed by a product label.
• Whether an applicant’s proposed labeling induces infringement.
• Whether a formulation difference affects pharmaceutical equivalence.
• Whether a process patent can be enforced against imported active ingredient or finished dosage forms.
• Whether a veterinary depot product infringes release-profile or polymer claims.

Settlement agreements can delay generic entry, permit licensed launch dates, or establish authorized-generic arrangements. Their economic value depends on the remaining patent term, market size, number of challengers, and whether the settlement includes non-compete or supply provisions. No biosimilar settlement framework applies because ivermectin is a small-molecule drug.

What FDA regulatory issues affect excipient selection?

FDA approval requires more than a plausible formulation concept. The sponsor must address inactive-ingredient safety, pharmaceutical equivalence, product performance, stability, manufacturing controls, and route-specific tolerability.

Key regulatory considerations include:

• Prior use of the excipient in the same route and dosage form.
• Maximum daily exposure.
• Local irritation and sensitization for topical products.
• Preservative efficacy and microbial limits.
• Nitrosamine and elemental impurity risk.
• Extractables and leachables from packaging.
• Excipient compatibility with ivermectin.
• Polymorphic and amorphous-form control.
• Content uniformity at low drug loading.
• Comparative dissolution or release testing.
• In vitro permeation for topical products.
• In vivo bioequivalence where required.

Novel excipients can provide stronger differentiation but increase development time and regulatory risk. For a low-cost drug such as ivermectin, the optimal commercial strategy often uses established excipients in a new combination, supported by robust performance data.

What licensing and partnership opportunities exist?

Ivermectin licensing opportunities are strongest in platform technologies rather than the active ingredient. Potential deal structures include:

1. Licensing a nanocrystal, amorphous-dispersion, or lipid-delivery platform for oral ivermectin.
2. Partnering with a topical formulation company for rosacea or dermatology products.
3. Licensing a long-acting veterinary depot technology to an animal-health manufacturer.
4. Supplying a proprietary excipient blend under a quality and exclusivity agreement.
5. Co-developing pediatric dispersible products with public-health organizations.
6. Licensing regional rights to products tailored to local manufacturing and distribution requirements.

The highest-value partnership candidates are manufacturers with existing regulatory infrastructure, veterinary field networks, dermatology sales forces, or access to low-cost high-volume production. A platform owner should seek milestone payments tied to formulation selection, regulatory submission, approval, and sales, rather than relying only on royalties from a commodity tablet.

What revenue exposure and competitive risks should investors assess?

Ivermectin revenue is fragmented across branded human products, generic tablets, veterinary products, and regional manufacturers. Public company exposure is often embedded in broader animal-health or dermatology portfolios rather than separately reported.

The main commercial risks are:

• Rapid price erosion after generic or authorized-generic entry.
• Limited willingness to pay for incremental bioavailability.
• Regulatory requirements for a new delivery system.
• Formulation patents that are narrow or easy to design around.
• Anthelmintic resistance affecting veterinary demand.
• Public-health procurement pressure in low-income markets.
• Product liability and misuse outside approved indications.
• Supply-chain dependence on low-cost API producers.
• Substitution by other antiparasitic agents or competing dermatology therapies.

A differentiated product is more likely to support premium pricing if it reduces dosing frequency, improves adherence, addresses a pediatric need, provides a clear topical tolerability advantage, or lowers veterinary labor and retreatment costs.

What is the best excipient and IP strategy for a new ivermectin product?

A practical development sequence is:

1. Select a defined commercial gap, such as pediatric dosing, topical tolerability, or veterinary duration.
2. Use a small excipient screen focused on solubility, stability, release, and route-specific safety.
3. Compare the lead formulation against a marketed reference product.
4. Generate pharmacokinetic, skin-deposition, palatability, or field-performance data.
5. File composition, process, and use claims before public disclosure.
6. Conduct a jurisdiction-specific freedom-to-operate review.
7. Align the formulation with an FDA 505(b)(2), ANDA, or new animal drug pathway.
8. Protect packaging, dosing devices, manufacturing controls, and trade secrets.
9. Secure manufacturing capacity for the critical excipient and API.
10. Build a launch strategy around a measurable benefit rather than ivermectin branding alone.

The most defensible product concepts combine a defined excipient system with a measurable performance result. Examples include a stable oral dispersion with reduced food effect, a topical cream with improved follicular retention and lower irritation, or a veterinary depot with a validated duration and acceptable residue profile.

Key Takeaways

• Ivermectin’s molecule-level exclusivity is expired; commercial value must come from formulation, delivery, process, device, or use claims.
• Oral tablets are difficult to premium-price because generic competition is broad and manufacturing is mature.
• Topical products offer stronger differentiation through cosmetic performance, skin deposition, tolerability, and packaging.
• Long-acting veterinary formulations have the largest potential for operational value but face residue, safety, and resistance-management requirements.
• Pediatric dispersible and taste-masked products address a clear usability gap.
• Strong formulation patents should define excipient ratios, physical properties, release behavior, stability, or pharmacokinetic performance.
• Ivermectin has no biosimilar risk. Paragraph IV and ANDA competition are the central U.S. legal risks.
• The best licensing targets are proprietary delivery platforms and animal-health technologies, not unmodified ivermectin tablets.
• FDA and veterinary regulators will scrutinize excipient safety, route-specific tolerability, stability, bioequivalence, and manufacturing control.
• Any ivermectin product positioned for COVID-19 prevention or treatment would face regulatory and evidentiary barriers because FDA has not approved ivermectin for that use.[6]

FAQs

Can cyclodextrins improve ivermectin solubility?

Yes. Cyclodextrins can increase apparent aqueous solubility through inclusion-complex formation. Their commercial value depends on achieving adequate drug loading, stability, tolerability, and a practical dosage volume.

Is an ivermectin nanocrystal product patentable?

Potentially. Patentability is stronger when the product claims define particle-size distribution, stabilizer ratios, manufacturing conditions, dissolution behavior, or demonstrated pharmacokinetic advantages. A generic claim to “nanoparticles containing ivermectin” is more vulnerable to prior-art and obviousness challenges.

Can a new ivermectin cream receive FDA approval without a new active ingredient?

Yes. The regulatory pathway could involve an ANDA if the product meets the applicable requirements for pharmaceutical equivalence and bioequivalence, or a 505(b)(2) application if the formulation relies on a different delivery system or requires new clinical support.

What is the most valuable ivermectin veterinary formulation opportunity?

Long-acting delivery is generally the most commercially differentiated opportunity. The product must show reliable duration, animal safety, acceptable residues, manageable withdrawal periods, and a resistance-management rationale.

Can excipient patents block generic ivermectin entry?

Yes, but only if enforceable claims cover the generic product or its use. A generic applicant may challenge listed patents through Paragraph IV certification or design around the claimed excipient system, process, or method of treatment.

References

1. U.S. Food and Drug Administration. (2022). Stromectol (ivermectin) tablets prescribing information. Merck Sharp & Dohme LLC.

2. U.S. Food and Drug Administration. (2024). Soolantra (ivermectin) cream prescribing information. Galderma Laboratories, L.P.

3. U.S. Food and Drug Administration. (2023). Sklice (ivermectin) lotion prescribing information. Arbor Pharmaceuticals, LLC.

4. World Health Organization. (2023). Ivermectin. WHO Model List of Essential Medicines and product information.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

6. U.S. Food and Drug Administration. (2021). FDA warns about using ivermectin to prevent or treat COVID-19. FDA Consumer Update.